Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Megestrol · 1 trial · 1 indication
Overall survival in months measured from date of starting treatment in core study to date of death for any reason.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Megestrol acetate | DRUG | Megestrol Acetate 160 mg oral tablets Qd |
| exemestane (Aromasin) | DRUG | exemestane (Aromasin) 25 mg oral tablets Qd |
Inclusion Criteria: * Previous participation in study 971-ONC-0028-080. Exclusion Criteria: * Subjects who had not previously participated in study 971-ONC-0028-080.
Top 20 of 92 competitors
Megestrol is a small molecule being studied for use in metastatic breast cancer. It is an investigational drug in Phase 3 clinical development, evaluated in postmenopausal women with this condition. The drug is being developed by Pfizer, Inc. (NYSE: PFE).
Megestrol is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 3 clinical development for metastatic breast cancer.
Megestrol is in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied for metastatic breast cancer in postmenopausal women. The Phase 3 trial has been completed.
Megestrol has one completed Phase 3 clinical trial, identified as NCT01237327. This multicenter follow-up study enrolled 84 postmenopausal women with metastatic breast cancer in China. The trial was active-controlled and did not use randomization or blinding.
Megestrol is a small molecule being studied for metastatic breast cancer. Its specific molecular target has not been disclosed in the available information, so its mechanism of action is not detailed here.